| HS Code | 613779 |
| Product Name | Trionycis Carapax Veterinary Grade API |
| Dosage Forms | Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions |
| Source | Dried shell of Trionyx sinensis (Chinese softshell turtle) |
| Appearance | Brownish-grey to dark brown fine powder or crystalline extract |
| Solubility | Slightly soluble in water; soluble in dilute acids and alkaline solutions |
| Particle Size | At least 95% passes through a 100-mesh sieve (150 µm) |
| Ph Range | 2.0 to 4.0 (1% w/v solution in dilute hydrochloric acid) |
| Storage Conditions | Store in tightly sealed containers, protected from moisture and light, at controlled room temperature 15–30°C |
| Veterinary Use Indication | Source of calcium and trace minerals for bone development and metabolic support in livestock, poultry, and companion animals |
| Injection Compatibility Note | Sterile filtered and pyrogen-free grade for parenteral formulations |
As an accredited Trionycis Carapax Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | Packaged in sealed, light-resistant, tamper-evident containers to ensure purity and stability, available in 25 kg drums. |
| Container Loading (20′ FCL) | Dry powder packed in sealed drums on pallets, securely block-stowed and braced in a 20′ FCL container. |
| Shipping | Trionycis Carapax Veterinary Grade API is shipped in sealed, tamper-evident containers with desiccants to maintain purity. Transport via temperature-controlled, secure freight, avoiding moisture and direct sunlight. All shipments comply with veterinary pharmaceutical regulations, with full documentation, traceability, and proper handling protocols to ensure safe, intact delivery worldwide. |
| Storage | Store Trionycis Carapax Veterinary Grade API in a tightly sealed, original container in a cool, dry, well-ventilated area, protected from light and moisture. Maintain temperature between 15–30°C. Avoid direct sunlight, freezing, and contact with incompatible materials. Keep away from food and animal feed. Once opened, minimize exposure to air and humidity. Use under clean conditions to preserve stability. |
| Shelf Life | Shelf Life: 36 months in original sealed container, stored in a cool, dry place away from direct sunlight and moisture. |
For immediate-release tablets intended for companion animals, the Trionycis Carapax Veterinary Grade API batch is first evaluated for powder flow using the compressibility index and Hausner ratio described in USP <616>. Direct compression is normally excluded when the Hausner ratio exceeds 1.34 and the compressibility index exceeds 23%; most lots of this mineralized organic powder reach that threshold unless the supplier has controlled the particle size distribution and reduced residual moisture to below 5.0% using a validated drying step monitored by USP <731>. Dry granulation by roller compaction is therefore the preferred tablet process. The API is screened through a 0.8 mm sieve, blended with a portion of microcrystalline cellulose, croscarmellose sodium, and colloidal silicon dioxide, and compacted into ribbons; the ribbons are milled to a granule size within 0.2–0.5 mm. The granules are then blended with the remaining excipients and compressed on a rotary tablet press fitted with B-tooling. Magnesium stearate is added last at 0.5–1.0% w/w to avoid over-lubrication, which delays disintegration and reduces tablet hardness. Tablet hardness is checked by USP <1217> after compression; disintegration is confirmed in water at 37±2°C within 30 minutes according to USP <701>, and content uniformity is evaluated by USP <905> with an acceptance value not exceeding 15.0. The finished product is an immediate-release tablet for oral administration; actual drug load is fixed by the approved dose for the target species, and no universal API-to-excipient ratio can be stated because the assay of this biological-source material varies between batches. Published compendial data for this exact formulation configuration is limited, so pilot batch release and registrability depend on the marketing authorisation file.
| Dosage form | Critical control point | Primary standard | Typical acceptance criterion |
|---|---|---|---|
| Tablets | Disintegration time in water | USP <701> | Complete within 30 minutes |
| Capsules | Uniformity of dosage units | USP <905> | Acceptance value ≤15.0 |
| Injections | Bacterial endotoxins | USP <85> | Route-specific limit |
| Premix | Sampling for homogeneity | ISO 6497 | Batch-specific CV limit |
| Powders | Uniformity of dosage units | USP <905> | Acceptance value ≤15.0 |
When the dose per hard capsule is low relative to the excipient mass, the primary technical risk is blend segregation during machine filling. The carapace-derived API has a broad particle size distribution and a tendency to adhere to metal contact surfaces, so direct powder filling frequently fails the USP <905> acceptance value. A two-stage ordered mixing method is therefore used: the API is first combined with fine lactose monohydrate at a 1:10 ratio and passed through a 0.4 mm screen, then diluted to 1:100 with a coarser lactose carrier in a tumble blender. Blend uniformity is monitored by sampling at 10 discharge intervals and testing by the same compendial method. Capsule filling is performed on a dosator-type encapsulator rather than a tamping-pin machine because the dosator compaction step reduces dusting, although over-compaction can alter plug porosity and delay dissolution; an initial plug compression force is therefore qualified by plotting dissolution against dosator setting. The finished product is an equine hard capsule, typically containing a dry blend rather than a granulated fill to avoid exposing the shell to residual moisture. For HPMC capsule shells, storage below 35% RH causes brittleness and above 65% RH causes shell softening; release testing includes the USP <701> disintegration test. Published pharmacopoeial data for this exact capsule configuration is limited, and dissolution acceptance criteria must be justified from pilot bioavailability or pilot dissolution data rather than an established monograph.
Parenteral dosage forms of Trionycis Carapax are constrained by the endotoxin burden of the starting material and the heat sensitivity of soluble peptide markers. The API is dispersed in Water for Injection and homogenized under high shear; insoluble mineral particles, primarily calcium carbonate and trace silicates, remain as a settleable fraction unless membrane clarification is applied. For sterile suspensions, particle size is reduced by wet milling to a median diameter below 10 µm, and the suspension is aseptically filled after filtration of dissolved components through a 0.22 µm membrane. For clear solutions, only the ultrafiltered soluble fraction can be used, which changes the assayed marker composition and requires revalidation of active content. Bacterial endotoxin testing is performed by USP <85> or Ph. Eur. 2.6.14; sterility is confirmed by USP <71> or Ph. Eur. 2.6.1. Terminal sterilization by saturated steam at 121°C for 15 minutes is not universally applicable because thermal denaturation of proteinaceous markers can reduce assay content; terminal heat exposure must be justified by forced degradation data. Osmolality is adjusted to the physiological range for the target species and verified by USP <785>. API-to-vehicle ratio is determined by the injection volume and target species body weight, not by a fixed formulation table. Published regulatory data for this specific injection configuration is limited, so each formulation is treated as a novel product for stability and compatibility purposes.
The main production-scale constraint is not API activity but homogeneity retention through the feed mill. The API is often delivered as a fine powder that separates from coarse carriers during transfer. A stepwise dilution is used, with the neat API first blended with ground limestone or corn starch at a 1:10 ratio in a paddle mixer, then extended to a 1:100 intermediate premix and finally to a 1:1000 feed inclusion where regional medicated feed rules permit. Sampling for mixer validation is performed with a sampling thief at 10 positions after 10 minutes of blending according to ISO 6497; homogeneity acceptance is based on the batch-specific coefficient of variation of the assayed marker compound under regional GMP for medicated feed, including 21 CFR 225 and the feed hygiene requirements of Regulation (EC) 183/2005. Carryover into non-target feed must be controlled by line segregation or validated flushing; published batch-specific carryover data for this API source are limited. The premix is packed in low-permeability bags and stored below 25°C and 60% RH to prevent hydration of the shell-derived mineral matrix. The finished product is a dry medicated premix for mixing into complete feed at the approved inclusion rate.
Powdered Trionycis Carapax formulations for in-water dosing are manufactured by co-milling the API with glucose monohydrate and a food-grade wetting agent. The co-milled blend is filled into low-moisture sachets and tested for uniformity of dosage units by USP <905>; sachet-to-sachet variation is typically the limiting quality attribute because the API tends to agglomerate after storage above 60% RH. The API-to-carrier ratio is set by the dose per sachet and the target drinking-water concentration; no fixed universal ratio is available. Reconstitution is performed in drinking water, but wetting time must be confirmed in each batch because the mineral-protein matrix becomes hydrophobic when overdried. Published data for this specific powder format is limited, so no single wetting time specification is fixed.
Because fine Trionycis Carapax powder dusts heavily during open feeding, a granulation step is introduced for ruminant top-dressing and oral drenching. The powder is granulated in a fluid-bed granulator with a binder solution of hypromellose or starch paste; inlet air temperature is selected below 60°C to avoid collapse of heat-sensitive organic nitrogen markers in the shell-derived matrix. Granule growth is monitored by sieve analysis, and the target fraction between 0.5 mm and 1.4 mm is selected because finer granules blow away during open feeding and coarser granules are not uniformly consumed by cattle. The granulation liquid-to-solid ratio is batch-specific; no fixed ratio can be given because the water absorption capacity of the shell-derived powder varies with source lot mineral content and previous drying. Drying continues until loss on drying by USP <731> is below the pre-established limit that prevents microbial proliferation; granules are then filled into unit-dose sachets. Dissolution or dispersion behaviour in rumen fluid is not described by a harmonized compendial method, so published data for this specific configuration is limited.
In aqueous oral solutions for poultry or weanling pigs, the primary technical barrier is hydrolytic degradation of protein and polysaccharide markers during ambient storage. The API is dissolved or suspended in purified water with pH adjustment using citrate or phosphate buffer; if preservation is required for multi-dose bottles, candidate preservatives must be screened for physical interactions with soluble carapace proteins. Benzalkonium chloride, for example, may precipitate anionic glycoprotein fractions, so its use is not assumed compatible; screening is performed by visual inspection and by USP <51> antimicrobial effectiveness testing. A nitrogen overlay in the headspace is applied during filling to reduce oxidative browning of phenolic and amine residues. The finished solution is tested for pH, osmolality, clarity, and microbial enumeration per Ph. Eur. 5.1.4. Long-term storage is evaluated at 25°C and 60% RH, with accelerated storage at 40°C and 75% RH, following the relevant VICH stability guideline. The API-to-solvent ratio is determined by the dose per millilitre for the target species and cannot be fixed across indications. Published data for this specific configuration is limited, so preservative choice and shelf-life are batch-specific.
Competitive Trionycis Carapax Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8615365186327 or mail to admin@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8615365186327
Email: admin@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Trionycis Carapax Veterinary Grade API is released in three model designations: TC-VG-100M, TC-VG-60C, and TC-VG-SE. TC-VG-100M is the micronized direct-compression and capsule-filling grade with laser-diffraction D90 ≤ 100 µm; TC-VG-60C is the coarse-cut premix and dry-powder grade with D90 ≤ 250 µm; TC-VG-SE is the vacuum-dried aqueous extract for granules, oral solutions, and liquid premixes, with ≥ 95% passage through an 850 µm sieve. The source material is cleaned carapace of Trionyx sinensis that is steam-softened, washed, dried, and comminuted before hot-water extraction. The extraction, concentration, drying, and milling steps are operated under veterinary GMP controls and are reviewed against 21 CFR 210, 21 CFR 211, ISO 9001:2015, and relevant clauses of ISO 14644 for cleanroom air classification during packaging of injectable-grade material.
The release specification for all models includes identification by thin-layer chromatography against a certified reference extract described in the ChP 2020 monograph for Trionycis Carapax. Loss on drying is controlled at ≤ 8.0% for the micronized grade, ≤ 9.0% for the coarse-cut grade, and ≤ 6.0% for the vacuum-dried extract. The assay marker is total polysaccharides expressed as D-glucose equivalents by a validated phenol-sulfuric acid method; the certificate reports the value in grams per 100 g and uses the same calibration reference for all models. Total nitrogen is determined by Kjeldahl and is reported as a marker for collagenous protein. Elemental impurities are controlled by USP <232> and USP <233>; the product-specific limits are ≤ 5 mg/kg lead, ≤ 2 mg/kg arsenic, ≤ 1 mg/kg cadmium, and ≤ 0.1 mg/kg mercury. Because the carapace naturally contains carbonate and phosphate mineral fractions, total ash is reported but is not interpreted as a purity index.
Unlike dibasic calcium phosphate anhydrous or precipitated calcium carbonate, this material is not a single-entity salt. The carapace matrix contains calcium phosphate and carbonate mineral phases associated with collagenous protein and sulfated polysaccharide fractions. Consequently, the ash value and nitrogen value move together in batch-to-batch trend charts, and the ratio of acid-soluble calcium to total nitrogen is monitored as a process consistency indicator. In comparative compendial terms, there is no USP/NF counterpart; formulation substitution for calcium carbonate without revalidation is not supported because the powder-bed density, aqueous dispersion viscosity, and disintegration response differ measurably from inorganic salts. The polysaccharide fraction also hydrates in aqueous media and contributes a viscosity rise that is absent from synthetic mineral excipients. Compared with purified botanical polysaccharide powders, the material contains a higher mineral residue and a measurable nitrogen fraction, which can affect wet-granulation endpoint detection and final tablet hardness.
The TC-VG-100M grade is intended for direct-compression tablets and capsule filling. The particle-size limit of D90 ≤ 100 µm is verified by laser diffraction; not more than 5.0% of the material is retained on a 200-mesh sieve. Moisture is controlled to ≤ 8.0% because higher moisture increases the cohesion index and reduces flow through a gravity-fed die table. On a production rotary tablet press fitted with 8 mm round standard concave tooling, the powder compresses to a target breaking force of 50–100 N at press speeds of 20–40 rpm. When the Hausner ratio exceeds 1.35, dosator-type capsule fillers show weight variation above ±5%; therefore, bulk and tapped density are recorded per USP <616> Method I on every batch. Colloidal silicon dioxide flow-aid addition is restricted to 0.5 wt% because higher concentrations increase ejection force and risk tooling wear. Friability is limited to ≤ 1.0% per USP <1216>, with tablets checked after 100 revolutions.
For capsule filling with TC-VG-100M, tamping stations are set to a low tamping force because over-compression creates a plug that resists ejection. In transfer-line audits, the main source of weight variability was not API particle size but electrostatic charging at relative humidity below 30%; the blending room is therefore maintained at 40–55% relative humidity. For formulations requiring higher active load or improved content uniformity, wet granulation with TC-VG-SE as a binder solution is preferred. The extract is dissolved or dispersed in purified water at 40–50 °C and sprayed onto a fluid-bed granulator at an inlet air temperature not exceeding 70 °C. The granules are dried to a final moisture of ≤ 2.5% before lubrication with magnesium stearate at 0.5–1.0 wt%. This route reduces segregation but increases disintegration time in USP <711> dissolution tests because the polysaccharide fraction forms a hydrated gel layer.
| Parameter | TC-VG-100M | TC-VG-60C | TC-VG-SE | Method |
|---|---|---|---|---|
| Appearance | Off-white to pale tan powder | Light tan coarse granulation | Yellow-brown dried extract | Visual |
| Particle size | D90 ≤ 100 µm, ≤ 5% retained on 200 mesh | D90 ≤ 250 µm | ≥ 95% through 850 µm sieve | Laser diffraction / sieve |
| Loss on drying | ≤ 8.0% | ≤ 9.0% | ≤ 6.0% | USP <731> |
| Bulk density | 0.35–0.55 g/cm³ | 0.50–0.75 g/cm³ | 0.40–0.60 g/cm³ | USP <616> Method I |
| Total polysaccharides | ≥ 15.0% | ≥ 10.0% | ≥ 20.0% | Phenol-sulfuric acid |
| Total nitrogen | ≥ 3.0% | ≥ 2.5% | ≥ 4.0% | Kjeldahl |
| Elemental impurities | Pb ≤ 5 mg/kg, As ≤ 2 mg/kg, Cd ≤ 1 mg/kg, Hg ≤ 0.1 mg/kg | Same | Same | USP <232>/USP <233> |
| Microbial limits | TAMC ≤ 1000 CFU/g, TYMC ≤ 100 CFU/g, E. coli absent in 1 g, Salmonella absent in 10 g | Same | Same | USP <61>/USP <62> |
Premix manufacturing with TC-VG-60C uses ribbon mixers with working volumes of 500–1000 L. The active is pre-blended with a portion of the carrier for 10 min, then combined with the remaining carrier and mixed for an additional 15 min. The carrier-to-API ratio is maintained between 1:5 and 1:20 by mass; ratios below 1:3 have produced dead-zone buildup on mixer walls during scale-up and have increased blend uniformity relative standard deviation above 5.0%. The premix should not be exposed to pelleting temperatures above 60 °C because proteinaceous material denatures and can form hard, water-insoluble aggregates. Silica or mineral oil dust suppressants are avoided when the premix is intended for aqueous administration. Published data for the exact combination of this API with amine-based additives in solid premixes is limited; compatibility studies are therefore required before formulation lock.
TC-VG-SE is produced by hot-water extraction followed by vacuum concentration and drying. The extract is heat-sensitive in solution; polysaccharide depolymerization begins to alter viscosity and marker content when the liquid is held above 80 °C for more than 4 h. Therefore, falling-film evaporators are operated under reduced pressure with product temperatures below 70 °C. For injectable solutions, the API is reconstituted in water-for-injection, adjusted to pH 5.5–7.0 with phosphate or citrate buffers, and filtered through 0.22 µm polyvinylidene fluoride membranes before terminal sterilization at 121 °C for 15 min. The bacterial endotoxin limit for the API is set at ≤ 0.25 EU/mg and is verified by kinetic chromogenic USP <85> assay. Visible and sub-visible particulate matter is controlled by USP <788>; filtration conditions are adjusted when polysaccharide aggregates exceed 10 µm after sterilization. Because the high-molecular-weight polysaccharide fraction can precipitate in saline vehicles, the formulation is not compounded in normal saline without a solubility study.
For injectable-grade TC-VG-SE, bioburden before terminal filtration is controlled to ≤ 10 CFU/100 mL. The filter membrane area is selected based on differential pressure and the polysaccharide load; if transmembrane pressure exceeds 1.0 bar before the full batch volume has passed, the batch is diverted because filter blockage indicates aggregate formation. After sterile filtration, the solution is filled into depyrogenated Type I glass vials and autoclaved. The final product is tested for sterility by USP <71> and for bacterial endotoxins by USP <85>; particulate matter is assessed by light obscuration per USP <788>. This route is not suitable for high-viscosity solutions above 10 cP, because filter throughput falls below the validated range.
Reformulation risk concentrates in compression profile, disintegration, and dispersion rheology rather than in active-content loss. The acid-insoluble ash fraction is higher than that of purified cellulose or starch, which alters tablet hardness at equivalent compression force. In comparative dissolution runs under USP <711>, tablets containing 30 wt% TC-VG-100M show a delay in release of co-formulated actives of more than 15 min relative to dicalcium phosphate placebo formulations. This delay is attributed to the hydrated polysaccharide layer. Disintegrant concentration and superdisintegrant selection are therefore pre-qualified before scale-up. When replacing botanical polysaccharide sources, the nitrogen content and mineral content require rebalancing of the formulation because the carapace API contributes both organic and inorganic components. Dry blending with amine-based additives should be avoided due to browning reactions under high-humidity storage.
For oral solutions and liquid premixes, TC-VG-SE is dispersed in purified water at 25–35 °C with a high-shear mixer operating at 1500–3000 rpm for 15 min. The dispersion is stabilized with sodium benzoate at 0.1% or potassium sorbate at 0.15% when not pasteurized. Because the polysaccharide fraction can settle on standing, suspending agents such as xanthan gum at 0.1–0.3% are used in multi-dose oral preparations. These liquid preparations are not interchangeable with injectable routes: the non-sterile production environment and preservative package do not meet the osmolarity criterion of USP <785> or the particulate limits of USP <788>.
